Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-01-17

FDA Approved: KYPROLIS — Supplemental Application (Onyx Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Kyprolis (carfilzomib) submitted by Onyx Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Kyprolis (carfilzomib)

Snippet

SUPPL AP for KYPROLIS (CARFILZOMIB)